JPRN-jRCT2080222538未知1 期
A multi-center, open-label, dose escalation, Phase 1 study of oral LGH447 in Japanese patients with relapsed and/or refractory hematologic malignancies
ovartis Pharma K.K.0 个研究点开始时间: 2014年6月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Confirmed diagnosis of relapsed and/or refractory MM for which no standard effective treatment options exist
排除标准
- •- Uncontrolled cardiovascular condition, including ongoing cardiac arrhythmias, congestive heart failure, angina, or myocardial infarction within the past 6 months
研究者
相似试验
已完成
不适用
A multicenter, open-label, dose escalation, Phase I study of LJM716 administered intravenously in combination with trastuzumab in patients with HER2 overexpressing metastatic breast cancer or gastric cancer (CLJM716X2102)breast cancer or gastric cancer10006291NL-OMON37081ovartis Pharma BV3
已完成
1 期
A study of selicrelumab (RO7009789) in combination with atezolizumab in participants with locally advanced and/or metastatic solid tumorsSolid tumorsCancerISRCTN62420110F. Hoffmann-La Roche Ltd140
已完成
1 期
A study of cibisatamab in participants with locally advanced and/or metastatic carcinoembryonic antigen positive solid tumorsCancerISRCTN58060459Genentech, Inc149
已完成
1 期
Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromesower-risk myelodysplastic syndromes (MDS)JPRN-jRCT2080224585Otsuka Pharmaceutical Co., LTD.30
已完成
1 期
A study to evaluate the safety, pharmacokinetics, pharmacodynamics and therapeutic activity of RO7009789 (selicrelumab) in combination with vanucizumab or bevacizumab in patients with metastatic solid tumorsCancerISRCTN35774409Genentech, Inc94